Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Buti

Showing results (271-280 of 387) with videos related to

Pageof 39
Sort By:
Scientific Reports|December 18, 2021
Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry reviewCamila A Picchio, Sabela Lens, Manuel Hernandez-Guerra, et al.
Journal of Hepatology|July 6, 2026
Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results of the PAGE-B cohortGeorge V Papatheodoridis, George Dalekos, Ramazan Idilman, et al.
Alimentary Pharmacology & Therapeutics|November 25, 2022
Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg-positive chronic hepatitis BJosef Wagner, Lilly Yuen, Margaret Littlejohn, et al.
Alimentary Pharmacology & Therapeutics|January 19, 2021
Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitisMaurizia R Brunetto, Ivana Carey, Benjamin Maasoumy, et al.
Hepatology (Baltimore, Md.)|January 22, 2011
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver diseaseYun-Fan Liaw, I-Shyan Sheen, Chuan-Mo Lee, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2014
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosisStefan Zeuzem, Vicente Soriano, Tarik Asselah, et al.
Scientific Reports|February 19, 2021
Sophisticated viral quasispecies with a genotype-related pattern of mutations in the hepatitis B X gene of HBeAg-ve chronically infected patientsMaria Francesca Cortese, Carolina González, Josep Gregori, et al.
Alimentary Pharmacology & Therapeutics|September 4, 2020
Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosisMilan J Sonneveld, Willem P Brouwer, Bettina E Hansen, et al.
Annals of Hepatology|October 4, 2025
A multinational survey of physician knowledge about management of chronic hepatitis CMohamed El-Kassas, Yusuf Yilmaz, Chun-Jen Liu, et al.
American Journal of Human Genetics|May 15, 2024
Joint host-pathogen genomic analysis identifies hepatitis B virus mutations associated with human NTCP and HLA class I variationZhi Ming Xu, Gnimah Eva Gnouamozi, Sina Rüeger, et al.
Pageof 39

Showing results (271-280 of 387) with videos related to

Sort By:
Pageof 39
Scientific Reports|December 18, 2021
Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry reviewCamila A Picchio, Sabela Lens, Manuel Hernandez-Guerra, et al.
Journal of Hepatology|July 6, 2026
Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results of the PAGE-B cohortGeorge V Papatheodoridis, George Dalekos, Ramazan Idilman, et al.
Alimentary Pharmacology & Therapeutics|November 25, 2022
Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg-positive chronic hepatitis BJosef Wagner, Lilly Yuen, Margaret Littlejohn, et al.
Alimentary Pharmacology & Therapeutics|January 19, 2021
Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitisMaurizia R Brunetto, Ivana Carey, Benjamin Maasoumy, et al.
Hepatology (Baltimore, Md.)|January 22, 2011
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver diseaseYun-Fan Liaw, I-Shyan Sheen, Chuan-Mo Lee, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2014
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosisStefan Zeuzem, Vicente Soriano, Tarik Asselah, et al.
Scientific Reports|February 19, 2021
Sophisticated viral quasispecies with a genotype-related pattern of mutations in the hepatitis B X gene of HBeAg-ve chronically infected patientsMaria Francesca Cortese, Carolina González, Josep Gregori, et al.
Alimentary Pharmacology & Therapeutics|September 4, 2020
Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosisMilan J Sonneveld, Willem P Brouwer, Bettina E Hansen, et al.
Annals of Hepatology|October 4, 2025
A multinational survey of physician knowledge about management of chronic hepatitis CMohamed El-Kassas, Yusuf Yilmaz, Chun-Jen Liu, et al.
American Journal of Human Genetics|May 15, 2024
Joint host-pathogen genomic analysis identifies hepatitis B virus mutations associated with human NTCP and HLA class I variationZhi Ming Xu, Gnimah Eva Gnouamozi, Sina Rüeger, et al.
Pageof 39